Teva Pharmaceutical Industries
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Teva Pharmaceutical Industries's revenues will grow 16.2% and EPS will compress 0.0%.
The average estimate for revenue is $5.05 billion. On the bottom line, the average EPS estimate is $1.25.
Last quarter, Teva Pharmaceutical Industries notched revenue of $4.99 billion. GAAP reported sales were 19% higher than the prior-year quarter's $4.21 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.28. GAAP EPS of $0.99 for Q2 were 55% higher than the prior-year quarter's $0.64 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 53.3%, 70 basis points better than the prior-year quarter. Operating margin was 21.4%, 40 basis points better than the prior-year quarter. Net margin was 17.3%, 360 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $20.51 billion. The average EPS estimate is $5.37.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,474 members out of 2,545 rating the stock outperform, and 71 members rating it underperform. Among 538 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 533 give Teva Pharmaceutical Industries a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Teva Pharmaceutical Industries is outperform, with an average price target of $50.80.
Can your retirement portfolio provide you with enough income to last? You'll need more than Teva Pharmaceutical Industries. Learn about crafting a smarter retirement plan in "The Shocking Can't-Miss Truth About Your Retirement." Click here for instant access to this free report.
- Add Teva Pharmaceutical Industries to My Watchlist.